FDA Approves Novocure’s Optune Lua® for Lung Cancer

 The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen

Results of the pivotal Phase 3 LUNAR trial represent the first substantial improvement in median overall survival in more than 8 years for this patient population

Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death

https://www.businesswire.com/news/home/20241015381082/en/FDA-Approves-Novocure%E2%80%99s-Optune-Lua%C2%AE-for-the-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer